{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:56:39Z","timestamp":1785783399309,"version":"3.56.0"},"reference-count":0,"publisher":"MJH Life Sciences","issue":"3806","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,5]]},"abstract":"<jats:p>Spiradenocarcinomas are rare malignant skin adnexal tumors. We describe a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4\/6 inhibitor. This case highlights the unique nature of spiradenocarcinomas as well as the potential benefit of targeted therapy.<\/jats:p>","DOI":"10.46883\/2024.25921022","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:47:18Z","timestamp":1718891238000},"page":"230-231","source":"Crossref","is-referenced-by-count":2,"title":["A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation"],"prefix":"10.46883","member":"25947","published-online":{"date-parts":[[2024,6,12]]},"container-title":["ONCOLOGY"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:47:20Z","timestamp":1718891240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancernetwork.com\/view\/a-rare-case-of-metastatic-spiradenocarcinoma-with-cdkn2a-mutation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":0,"journal-issue":{"issue":"3806","published-online":{"date-parts":[[2024,6,11]]},"published-print":{"date-parts":[[2024,6,5]]}},"URL":"https:\/\/doi.org\/10.46883\/2024.25921022","relation":{},"ISSN":["0890-9091"],"issn-type":[{"value":"0890-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,5]]}}}